NCT06052956
Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses
At risk: Primary completion moved 12 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria shortened, about 3 words Show 4 more changesShow less
- Enrollment increased: 120 → 150 participants
- Interventions modified
- Secondary endpoints: 3 to 1
- Study description expanded, about 32 words
Notable Primary and study completion pushed from Jun 30, 2031 to Jun 30, 2032 Show 4 more changesShow less
- Start date: Jul 15, 2026 to Jul 15, 2027
- Eligibility criteria expanded, about 9 words
- Secondary endpoints: details revised at 3 of 3 entries
- Study description revised
- Notable Primary and study completion dates: Nov 15, 2030 to Jun 30, 2031
- Start date: Dec 15, 2025 to Jul 15, 2026
- Minor Enrollment target: 90 to 120
- Primary and study completion dates: Nov 2030 to Nov 15, 2030
- Start date: Dec 2025 to Dec 15, 2025
- Notable Eligibility criteria expanded, about 12 words
- Primary endpoint revised
- Secondary endpoints revised (3)
- Study description shortened, about 47 words
Show 3 earlier versionsHide 3 earlier versions
- Notable Primary and study completion dates: Dec 2029 to Nov 2030
- Start date: Jan 2025 to Dec 2025
- Notable Enrollment target: 60 to 90
- Primary and study completion dates: Apr 2028 to Dec 2029
- Start date: May 2024 to Jan 2025
- Minor Study title shortened, about 6 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
Each subject in this arm will receive standard of care abscess drainage, methylene blue, lipid emulsion, and laser illumination at an optical power defined by their abscess size.
Each subject in this arm will receive standard of care abscess drainage, methylene blue, lipid emulsion, optical spectroscopy, and laser illumination. The optical power for laser illumination will be determined by their abscess morphology and the results of optical spectroscopy.
Each subject in this arm will receive standard of care abscess drainage, inert blue blue dye, lipid emulsion, and fiber insertion without laser illumination.
Drugs: Methylene Blue, Lipid Emulsion, Inert blue dye
Devices: Insertion of optical fiber, Laser Illumination (pre-defined dose), Optical Spectroscopy Measurement, Laser Illumination (patient-specific dose)
Procedures: Standard of care abscess drainage
Sites
2 sites in 1 country